Clinical Trials Directory

Trials / Completed

CompletedNCT01054768

Antioxidant Therapy to Reduce Inflammation in Sickle Cell Disease

Status
Completed
Phase
Phase 2
Study type
Interventional
Enrollment
37 (actual)
Sponsor
UCSF Benioff Children's Hospital Oakland · Academic / Other
Sex
All
Age
10 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to determine whether alpha-lipoic acid and acetyl-L-carnitine will lower systemic inflammation in patients with Sickle Cell Disease by reducing oxidative stress, which will result in a decrease in the frequency of vaso-occlusive pain episodes and improve their quality of life.

Detailed description

People with sickle cell disease have more inflammation (a response of body tissues to injury or irritation) than people without sickle cell disease. This inflammation can be measured in the blood by checking the level of a protein called C reactive protein as well as other changes we see in blood due to inflammation (such as changes in platelets and other cells). There is even more inflammation during sickle-related complications (like pain or acute chest syndrome). We want to test if inflammation in people with sickle cell disease can be reduced by the use of antioxidant compounds. Antioxidants are nutrients (certain vitamins, minerals and enzymes) that can counteract the effects of oxidative stress arising from free radicals in our cells. The formation of free radicals is a normal cell process, but uncontrolled oxidative stress can cause problems for us. One such harmful problem is inflammation. We know from other research studies that antioxidants help with some conditions related to inflammation. In this study the antioxidant being tested is a combination of alpha-lipoic acid and acetyl-L-carnitine, both of which are natural parts of many of the foods we eat and are needed by our cells to make energy from food.

Conditions

Interventions

TypeNameDescription
DRUGalpha-lipoic acid and acetyl-L-carnitinenone to report
DRUGControlnone to report

Timeline

Start date
2009-08-01
Primary completion
2013-04-01
Completion
2013-04-01
First posted
2010-01-22
Last updated
2021-08-03
Results posted
2021-08-03

Locations

1 site across 1 country: United States

Source: ClinicalTrials.gov record NCT01054768. Inclusion in this directory is not an endorsement.